• Je něco špatně v tomto záznamu ?

N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer

M. Zahradnikova, I. Ihnatova, E. Lattova, L. Uhrik, E. Stuchlikova, R. Nenutil, D. Valik, M. Nalezinska, J. Chovanec, Z. Zdrahal, B. Vojtesek, L. Hernychova, MV. Novotny

. 2021 ; 230 (-) : 103964. [pub] 20200906

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019476

A number of studies have reported aberrant glycosylation in connection with malignancy. Our investigation further expands on this topic through the examination of N-glycans, which could be associated with the resistance of advanced stage, high-grade non-mucinous ovarian cancer to platinum/taxane based chemotherapy. We used tissue samples of 83 ovarian cancer patients, randomly divided into two independent cohorts (basic and validation). Both groups involved either cases with/without postoperative tumor residue or the cases determined either resistant or sensitive to this chemotherapy. In the validation cohort, preoperative serum samples were also available. N-glycans released from tumors and sera were permethylated and analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The MS analysis yielded a consecutive detection of 68 (tissue) and 63 (serum) N-glycan spectral signals. Eight of these were found to be differentially abundant in tissues of both independent cohorts including the cases with a postoperative cancer residue. One of these glycans was detected as differentially abundant in sera of the validation cohort. No statistically significant differences in intensities due to the same N-glycans were found in the cases without postoperative macroscopic residues in either the basic or validation cohort. From the biochemical point of view, the statistically significant N-glycans correspond to the structures carrying bisecting (terminal) GlcNAc residue and tetra-antennary structures with sialic acid and/or fucose residues. Among them, six tissue N-glycans could be considered potential markers connected with a resistance to chemotherapy in ovarian cancer patients. The prediction of primary resistance to standard chemotherapy may identify the group of patients suitable for alternative treatment strategies. SIGNIFICANCE: Drug resistance has become a major impediment to a successful treatment of patients with advanced ovarian cancer. The glycomic measurements related to cancer are becoming increasingly popular in identification of the key molecules as potential diagnostic and prognostic indicators. Our report deals with identification of differences in N-glycosylation of proteins in tissue and serum samples from the individuals showing sensitivity or resistance to platinum/taxane-based chemotherapy. The detection sensitivity to chemotherapy is vitally important for these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019476
003      
CZ-PrNML
005      
20210830101039.0
007      
ta
008      
210728s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jprot.2020.103964 $2 doi
035    __
$a (PubMed)32898699
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Zahradnikova, Martina $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec7, 656 53 Brno, Czech Republic
245    10
$a N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer / $c M. Zahradnikova, I. Ihnatova, E. Lattova, L. Uhrik, E. Stuchlikova, R. Nenutil, D. Valik, M. Nalezinska, J. Chovanec, Z. Zdrahal, B. Vojtesek, L. Hernychova, MV. Novotny
520    9_
$a A number of studies have reported aberrant glycosylation in connection with malignancy. Our investigation further expands on this topic through the examination of N-glycans, which could be associated with the resistance of advanced stage, high-grade non-mucinous ovarian cancer to platinum/taxane based chemotherapy. We used tissue samples of 83 ovarian cancer patients, randomly divided into two independent cohorts (basic and validation). Both groups involved either cases with/without postoperative tumor residue or the cases determined either resistant or sensitive to this chemotherapy. In the validation cohort, preoperative serum samples were also available. N-glycans released from tumors and sera were permethylated and analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The MS analysis yielded a consecutive detection of 68 (tissue) and 63 (serum) N-glycan spectral signals. Eight of these were found to be differentially abundant in tissues of both independent cohorts including the cases with a postoperative cancer residue. One of these glycans was detected as differentially abundant in sera of the validation cohort. No statistically significant differences in intensities due to the same N-glycans were found in the cases without postoperative macroscopic residues in either the basic or validation cohort. From the biochemical point of view, the statistically significant N-glycans correspond to the structures carrying bisecting (terminal) GlcNAc residue and tetra-antennary structures with sialic acid and/or fucose residues. Among them, six tissue N-glycans could be considered potential markers connected with a resistance to chemotherapy in ovarian cancer patients. The prediction of primary resistance to standard chemotherapy may identify the group of patients suitable for alternative treatment strategies. SIGNIFICANCE: Drug resistance has become a major impediment to a successful treatment of patients with advanced ovarian cancer. The glycomic measurements related to cancer are becoming increasingly popular in identification of the key molecules as potential diagnostic and prognostic indicators. Our report deals with identification of differences in N-glycosylation of proteins in tissue and serum samples from the individuals showing sensitivity or resistance to platinum/taxane-based chemotherapy. The detection sensitivity to chemotherapy is vitally important for these patients.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glykosylace $7 D006031
650    _2
$a lidé $7 D006801
650    12
$a nádory vaječníků $x farmakoterapie $7 D010051
650    12
$a platina $7 D010984
650    _2
$a polysacharidy $7 D011134
650    _2
$a spektrometrie hmotnostní - ionizace laserem za účasti matrice $7 D019032
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ihnatova, Ivana $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec7, 656 53 Brno, Czech Republic; Recetox, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Lattova, Erika $u Central European Institute of Technology, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Uhrik, Lukas $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec7, 656 53 Brno, Czech Republic
700    1_
$a Stuchlikova, Eliska $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec7, 656 53 Brno, Czech Republic
700    1_
$a Nenutil, Rudolf $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec7, 656 53 Brno, Czech Republic
700    1_
$a Valik, Dalibor $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec7, 656 53 Brno, Czech Republic
700    1_
$a Nalezinska, Monika $u Department of Gynecologic Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Chovanec, Josef $u Department of Gynecologic Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Zdrahal, Zbynek $u Central European Institute of Technology, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Vojtesek, Borivoj $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec7, 656 53 Brno, Czech Republic
700    1_
$a Hernychova, Lenka $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec7, 656 53 Brno, Czech Republic. Electronic address: lenka.hernychova@mou.cz
700    1_
$a Novotny, Milos V $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec7, 656 53 Brno, Czech Republic; Department of Chemistry, Indiana University, 800 E. Kirkwood Avenue, Bloomington, IN 47405, USA. Electronic address: novotny@indiana.edu
773    0_
$w MED00166847 $t Journal of proteomics $x 1876-7737 $g Roč. 230, č. - (2021), s. 103964
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32898699 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101039 $b ABA008
999    __
$a ok $b bmc $g 1690324 $s 1139922
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 230 $c - $d 103964 $e 20200906 $i 1876-7737 $m Journal of proteomics $n J Proteomics $x MED00166847
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...